GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating GNAq protein mutations at codon 209 are found in uveal melanomas.
• Thyroid carcinomas and uveal melanomas share frequent MAP kinase pathway-activating mutations.
• Activating GNAS1 mutations occur in thyroid adenomas, suggesting a potential role for GNAq in thyroid nodules.

Purpose of the Study:

• To investigate the presence of GNAq mutations in exon 5, codon 209, within thyroid papillary carcinomas and hyperfunctioning thyroid nodules.
• To determine if GNAq mutations contribute to the development of thyroid follicular neoplasms.
• To explore the molecular basis of MAP-kinase pathway activation in thyroid carcinomas lacking RET-PTC, BRAF, or RAS mutations.

Main Methods:

• Screening of 32 RET/PTC, BRAF, and RAS-negative thyroid papillary carcinomas for GNAq mutations.
• Evaluation of 13 hyperfunctioning thyroid nodules for GNAq mutations.
• Focus on exon 5, codon 209, a known hotspot for GNAq activating mutations.

Main Results:

• No GNAq mutations were identified in any of the evaluated thyroid papillary carcinomas.
• No GNAq mutations were detected in the examined hyperfunctioning thyroid nodules.
• The study found no evidence supporting a role for GNAq mutations in thyroid follicular neoplasms.

Conclusions:

• GNAq mutations do not appear to be a significant factor in the pathogenesis of thyroid papillary carcinomas or benign hyperfunctioning thyroid nodules.
• The findings align with existing literature indicating a lack of GNAq hotspot mutations in thyroid cancers.
• Further research is needed to elucidate the molecular mechanisms driving MAP-kinase pathway activation in thyroid carcinomas that are negative for common mutations (RET-PTC, BRAF, RAS).